Organovo (ONVO) issued a business update. With the closing of the sale of its FXR Program to Lilly (LLY), Organovo has received upfront payments and anticipates future milestone payments. The company believes it is well-positioned to repeat the FXR314 success with another IBD opportunity.
Organovo now expects to establish an operating cadence that leverages existing capital at a rate sufficient to push through the end of fiscal 2026. The company expects to report its full year financials for the fiscal year ended March 31, 2025, on or about June 6-10, 2025.
Shares of Organovo are up 3% in pre-market trade on Thursday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.